TY - JOUR
T1 - Serum Immunoglobulin A Response to Human Papillomavirus Type 16 Virus-Like Particles in Human Immunodeficiency Virus (HFV)-Positive and High-Risk HIV-Negative Women
AU - Viscidi, Raphael P.
AU - Ahdieh-Grant, Linda
AU - Schneider, Michael F.
AU - Clayman, Barbara
AU - Massad, L. Stewart
AU - Anastos, Kathryn M.
AU - Burk, Robert D.
AU - Minkoff, Howard
AU - Palefsky, Joel
AU - Levine, Alexandra
AU - Strickler, Howard
PY - 2003/12/15
Y1 - 2003/12/15
N2 - Serum samples from 2008 human immunodeficiency virus (HIV)-positive and 551 HIV-negative women were tested for immunoglobulin A (IgA) to human papillomavirus (HPV) type 16 capsids. IgA seropositivity was lower than previously reported IgG seropositivity (7% vs. 51%), but, like IgG antibodies, HPV 16 IgA was associated with sexual behavior, cervicovaginal HPV 16 DNA, and cytological abnormalities. IgA seropositivity was higher in HIV-positive women than in HIV-negative women (7.7% vs. 4.9%; P = .02), but the association was lost after adjustment for HPV 16 cervicovaginal infection. IgA, but not IgG, seropositivity was associated with progression to high-grade cytological abnormalities (relative hazard [RH], 2.2 [95% confidence interval, 1.2-4.2]), raising the possibility that an IgA response to HPV 16, as described for other DNA viruses, may be a marker of persistent viral replication. The risk of incident infection with non-16-related HPV types was increased in IgA seropositive women (RH, 1.8 [95% confidence interval, 1.3-2.6]), compared with seronegative women (RH, 2.2 [95% confidence interval, 0.9-5.4]), but there was no difference in the risk of incident HPV 16 or HPV 16-related infections. This may be evidence of partial type-specific or clade-specific immunity conferred by seropositivity to HPV 16 capsids.
AB - Serum samples from 2008 human immunodeficiency virus (HIV)-positive and 551 HIV-negative women were tested for immunoglobulin A (IgA) to human papillomavirus (HPV) type 16 capsids. IgA seropositivity was lower than previously reported IgG seropositivity (7% vs. 51%), but, like IgG antibodies, HPV 16 IgA was associated with sexual behavior, cervicovaginal HPV 16 DNA, and cytological abnormalities. IgA seropositivity was higher in HIV-positive women than in HIV-negative women (7.7% vs. 4.9%; P = .02), but the association was lost after adjustment for HPV 16 cervicovaginal infection. IgA, but not IgG, seropositivity was associated with progression to high-grade cytological abnormalities (relative hazard [RH], 2.2 [95% confidence interval, 1.2-4.2]), raising the possibility that an IgA response to HPV 16, as described for other DNA viruses, may be a marker of persistent viral replication. The risk of incident infection with non-16-related HPV types was increased in IgA seropositive women (RH, 1.8 [95% confidence interval, 1.3-2.6]), compared with seronegative women (RH, 2.2 [95% confidence interval, 0.9-5.4]), but there was no difference in the risk of incident HPV 16 or HPV 16-related infections. This may be evidence of partial type-specific or clade-specific immunity conferred by seropositivity to HPV 16 capsids.
UR - http://www.scopus.com/inward/record.url?scp=9144273194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144273194&partnerID=8YFLogxK
U2 - 10.1086/379975
DO - 10.1086/379975
M3 - Article
C2 - 14673762
AN - SCOPUS:9144273194
SN - 0022-1899
VL - 188
SP - 1834
EP - 1844
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 12
ER -